Skip to main content
AMGN
NASDAQ Life Sciences

EVP Sells $20.7M in Amgen Stock Following Option Exercise

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$386.5
Mkt Cap
$207.918B
52W Low
$261.43
52W High
$391.29
52W Position info
48% above low
Off High info
1.2% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

AMGN sits 48% above its 52-week low of $261.43.

Summary

Amgen's EVP of Operations, Esteban Santos, sold $20.7 million worth of common stock after exercising options, reducing his direct holdings.


Key Events · Ownership and Investor Activity · AMGN

  • Executive Sells Significant Stake

    Esteban Santos, Amgen's EVP of Operations, sold 54,792 shares of common stock for a total value of $20.7 million.

  • Option Exercise Preceded Sale

    The sale followed the exercise of options to acquire 54,792 shares for $9.27 million, indicating a net cash-out from the transaction.

  • Discretionary Sale Near 52-Week High

    The transaction was not executed under a 10b5-1 plan and occurred while Amgen's stock is trading near its 52-week high, suggesting the executive is locking in profits.


Analysis · AMGN · Life Sciences

This Form 4 filing indicates a significant sale of Amgen stock by Esteban Santos, EVP of Operations. While a portion of the $20.7 million sale was likely to cover the exercise price of options and associated taxes, the transaction represents a substantial cash-out by a key executive. The sale occurred as Amgen's stock trades near its 52-week high, suggesting the executive is realizing gains. This discretionary sale, not under a 10b5-1 plan, could be interpreted by investors as a slightly negative signal regarding insider sentiment, despite the routine nature of option exercises.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMGN was trading at $386.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $207.9B. The 52-week trading range was $261.43 to $391.29. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $438.50 info
Change: -$38.90 (-8%) info
Market Cap: $235.643B info
AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $438.50 info
Change: -$26.42 (-6%) info
Market Cap: $235.643B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $438.50 info
Change: -$24.50 (-5%) info
Market Cap: $235.643B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $438.50 info
Change: -$22.07 (-5%) info
Market Cap: $235.643B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $438.50 info
Change: -$10.29 (-2%) info
Market Cap: $235.643B info